Journal
CELL HOST & MICROBE
Volume 30, Issue 4, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.chom.2022.03.016
Keywords
-
Categories
Funding
- Vedanta Biosciences Inc.
- Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) [4500002475, IDSEP160030]
- Assistant Secretary for Preparedness and Response (ASPR)/Biomedical Advanced Research and Development Authority (BARDA)
- Wellcome Trust
- Vedanta Biosciences - Vedanta Biosciences, Inc. (Cambridge, MA, USA)
Ask authors/readers for more resources
Manipulating the gut microbiota through fecal microbiota transplantation shows promise in treating certain diseases. Live biotherapeutic products consisting of defined bacterial strains have potential as an alternative therapeutic option.
Manipulation of the gut microbiota via fecal microbiota transplantation (FMT) has shown clinical promise in diseases such as recurrent Clostridioides difficile infection (rCDI). However, the variable nature of this approach makes it challenging to describe the relationship between fecal strain colonization, corresponding microbiota changes, and clinical efficacy. Live biotherapeutic products (LBPs) consisting of defined consortia of clonal bacterial isolates have been proposed as an alternative therapeutic class because of their promising preclinical results and safety profile. We describe VE303, an LBP comprising 8 commensal Clostridia strains under development for rCDI, and its early clinical development in healthy volunteers (HVs). In a phase 1a/b study in HVs, VE303 is determined to be safe and well-tolerated at all doses tested. VE303 strains optimally colonize HVs if dosed over multiple days after vancomycin pretreatment. VE303 promotes the establishment of a microbiota community known to provide colonization resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available